There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.

 
Web www.patentalert.com

< Vascular endothelial cell growth inhibitor, VEGI-192a

< Heterocyclic and carbonate derivatives of NDGA and their use as new anti-HIV and anti-cancer agents

> Diagnostic markers, especially for in vivo imaging and assays and methods of use thereof

> Fusion antibodies that cross the blood-brain barrier in both directions
~ 00617